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Abstract: NF-YA, the regulatory subunit of the trimeric transcription factor (TF) NF-Y, is regulated 
by alternative splicing (AS) generating two major isoforms, “long” (NF-YAl) and “short” (NF-YAs). 
Muscle cells express NF-YAl. We ablated exon 3 in mouse C2C12 cells by a four-guide 
CRISPR/Cas9n strategy, obtaining clones expressing exclusively NF-YAs (C2-YAl-KO). C2-YAl-KO 
cells grow normally, but are unable to differentiate. Myogenin and—to a lesser extent, MyoD— 
levels are substantially lower in C2-YAl-KO, before and after differentiation. Expression of the 
fusogenic Myomaker and Myomixer genes, crucial for the early phases of the process, is not 
induced. Myomaker and Myomixer promoters are bound by MyoD and Myogenin, and Myogenin 
overexpression induces their expression in C2-YAl-KO. NF-Y inactivation reduces MyoD and 
Myogenin, but not directly: the Myogenin promoter is CCAAT-less, and the canonical CCAAT of 
the MyoD promoter is not bound by NF-Y in vivo. We propose that NF-YAl, but not NF-YAs, 
maintains muscle commitment by indirectly regulating Myogenin and MyoD expression in C2C12 
cells. These experiments are the first genetic evidence that the two NF-YA isoforms have 
functionally distinct roles. 
Keywords: splicing isoforms; CRISPR-Cas9; exon deletion; NF-Y; muscle differentiation; C2C12 
cells 
 
1. Introduction 
Cell specification and differentiation during development of multicellular organisms is a 
complex set of events resulting in the formation of organs, whose physiology is maintained by a 
balance of cell proliferation and differentiation. A paradigmatic example of these phenomena is 
formation of skeletal muscle. In the case of mammals—mouse in particular—the process begins at 
early developmental stages, proceeding through embryonic, fetal and adult stages [1,2]. Sequence-
specific transcription factors—TFs—play a central role in specifying the identities of myoblasts, their 
migration to different body locations, organization and the capacity to self-renew and differentiate 
into myotubes. These properties are key to guarantee maintenance and functionality of the different 
muscles throughout the lifespan of the organism, including repair after injury in adult life. A set of 
four key TFs —MyoD, Myf5, Myogenin, MRF4, termed myogenic regulatory factors (MRFs)—have 
been identified and thoroughly studied by genetic and biochemical means for their capacity to specify 
myoblasts identity [3,4]. During development, PAX3/7 are located upstream of MRFs [5]; 
downstream are many TFs, such as the MADS box MEF2A/C/D [6,7], the bHLH ID1/3 [8–10] and 
SNAI1 [11], the HOX SIX1/4/5 [12–15], STAT3 [16], NFIX [17,18] and the ZNF KLF2/4/5 [19,20]. Unlike 
MRFs, most of these TFs are not expressed predominantly in muscle cells and are equally important 
for development and differentiation of other tissues and organs [21–25]. 
Cells 2020, 9, 789 2 of 21 
 
NF-Y is an evolutionarily conserved heterotrimer formed by the sequence-specific NF-YA and 
the Histone Fold Domain—HFD—NF-YB/NF-YC [26]. The sequence recognized by NF-Y is the 
CCAAT box, which plays an important role in the activation of 25%–30% of mammalian genes. NF-
Y has been classified as ”pioneer” TF, in mammals and plants [27–31]. NF-YA is the regulatory 
subunit; it is alternatively spliced, generating two major isoforms “short” (NF-YAs) and “long” (NF-
YAl), differing in 28 amino acids coded by exon 3 [32]. This stretch is located at the N-terminus of the 
protein, in the Gln-rich transactivation domain (TAD). NF-YAs and NF-YAl have identical subunits-
interactions and DNA-binding properties in vitro; ChIP-seq from cells harboring predominantly 
either one of the two isoforms showed recovery of peaks enriched in CCAAT. The isoforms are 
expressed at various levels in different tissues and cell lines [32,33]. Importantly, no cell line has been 
so far described lacking NF-YA—nor the HFDs—and NF-YA inactivation was reported to be fatal to 
cells [28,34]. NF-YAl is the predominant isoform in muscle C2C12 cells: it is abundant in proliferating 
cells, but it drops to low levels following terminal differentiation to myotubes, unlike the HFD 
partners [35–37]. Highly reduced NF-YA protein was found in myotubes of adult mice [38]. This 
suggested that genes up-regulated in the terminal phases of muscle differentiation are either CCAAT-
less or not NF-Y-dependent, whereas the trimer activates cell-cycle and growth-promoting genes 
required during the proliferative state. However, overexpression of NF-YAl led to improved 
differentiation of C2C12 [39], suggesting that NF-YAl does take part in the differentiation process. 
For decades, C2C12 myoblast cells have represented an informative tool to identify genes 
involved in muscle differentiation [40]. Ablation of the whole NF-YA gene is early embryonic lethal 
[41], and KO in stable cell lines could not be generated so far. We investigated the role of NF-YAl by 
genetically ablating exon 3, leading to the production of an intact NF-YAs. We successfully generated 
homozygous C2C12 lines expressing only NF-YAs and went on to study differentiation properties. 
2. Materials and Methods 
2.1. Cell Culture and Proliferation Assay 
Mouse myoblast cells (C2C12, ATCC) were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS, Gibco-Thermo Fisher Scientific), 4 mM L-
Glutamine, 100 units/mL penicillin and 100 µg/mL streptomycin (GM, growth medium), in a 
humidified 5% CO2 atmosphere at 37 °C. C2C12 cells differentiation was induced plating cells in DMEM 
with 2% horse serum (Gibco-Thermo Fisher Scientific), 4 mM L-Glutamine, 100 units/mL penicillin and 
100 µg/mL streptomycin (DM, differentiation medium). Proliferation assay was performed by plating 
1.5 × 105 cells into a 12-well plate and counting every 24 h for 3 days, using the Trypan Blue dye 
exclusion test. All data were gathered from at least three independent biological replicates. Multiple 
comparisons were performed using the One-way ANOVA test. 
2.2. Derivation of C2-YAl-KO Clones 
To delete the exon 3 of NF-YA gene in C2C12 cells, four guide RNAs (gRNAs) were designed to 
simultaneously target the two flanking introns by using the online tool https://zlab.bio/guide-design-
resources. Potential off-target sites were monitored by the online tool https://crispr.cos.uni-
heidelberg.de: Table S1 shows the results of such analysis for the four guides. The selected gRNAs had 
no common off-target sites and were cloned in the two plasmids pX330A_D10A-1x2_ac and pX330A_ 
D10A-1x2_bd, following the Multiplex CRISPR/Cas9n Assembly System Kit protocol [42]. 1 × 106 C2C12 
cells were transfected with 3 µg of the two gRNAs/CRISPR/Cas9n plasmids by electroporation and 
plated at low density. 72 h after transfection, single clones were picked, expanded and screened. 
For DNA extraction, cells from the individual clones were washed with PBS, collected by scraping, 
lysed in 100 µL ice-cold lysis buffer (40 mM Tris-HCl, 2 mM EDTA, 0.08% SDS, 80 mM NaCl, 0.5 µg/µL 
Proteinase K) and incubated overnight at 37 °C in agitation. To precipitate DNA, 100 µL of ice-cold 2-
propanol and 0.3 M NaAc were added, samples were mixed and centrifuged at 13,000 rpm for 30 min 
at 4 °C. The pellet was washed with 150 µL of 70% ethanol, centrifuged at 13,000 rpm for 30 min at 4 
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°C. Supernatant was discarded, the pellet was dried and resuspended in 30 µL H2O. The resulting 
DNAs were then screened for positive exon 3 deletion by PCR. 
We screened a total of 335 individual clones and obtained 2 independent homozygously edited 
clones. 
2.3. Protein Extraction and Western Blot Analysis 
For Whole Cell Extracts preparation, cells were pelleted by centrifugation, resuspended in ice-cold 
RIPA buffer (10 mM TrisHCl pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 0.1% SDS, 0.1% sodium deoxycholate, 
140 mM NaCl, 1% Triton X-100, 1 mM PMSF, Protease inhibitor cocktail) and incubated for 30 min on 
ice, with occasional shaking. Samples were centrifuged at 13,000 rpm for 10 min at 4°C and the 
supernatant recovered and quantified using the Bradford protein assay. 
20 µg of extracts were loaded on a 4–10% SDS-polyacrylamide gel and analyzed by Western blot 
using primary antibodies and a peroxidase-conjugate secondary antibody (Sigma-Aldrich). Primary 
antibodies: anti-NF-YA (G-2, Santa Cruz), anti-NF-YB (GeneSpin), anti-NF-YC (home-made) anti-
Vinculin (H-10, Santa Cruz), anti-MyHCs (MF20, DHSB), anti-Myogenin (IF5D, DHSB), anti-MyoD (C-
20, Santa Cruz), anti-Myf5 (C-20, Santa Cruz), anti-Pax3 (DHSB), anti-Snai1 (C15D3, Cell Signaling). 
Western blot experiments were performed on three independent biological replicates. 
2.4. Reverse Transcriptase PCR and real-time PCR 
RNA was isolated by the Tri Reagent (Sigma-Aldrich) protocol according to the manufacturer’s 
instruction. The cDNA was produced starting from 1 µg of total RNA using the MMLV Reverse 
Transcription Mix (GeneSpin) and used for real-time PCR (SYBR® Green Master Mix, Bio-rad 
Laboratories) analysis. Real-time PCRs were performed with oligonucleotides designed to amplify 100–
200 bp fragments (Table S2). The housekeeping gene Rsp15a was used to normalize expression data. 
The relative sample enrichment was calculated with the formula 2–(ΔΔCt), where ΔΔCt = [(Ct sample – Ct 
Rps15a)x − (Ct sample – Ct Rps15a)y], x = sample and y = sample control. RT-qPCR analyses were 
performed on three independent biological replicates. For ChIP experiments, we figured out the 
percentage of input immunoprecipitated by NF-YB and nc (negative control) antibodies. Results of 
three independent experiments were represented as Fold change (Fc) between NF-YB sample and nc 
sample as: %Input NF-YB/%Input nc. 
2.5. Flow Cytometry Analyses 
Cells were harvested by trypsinization and washed in PBS, fixed in ice-cold 70% ethanol and stored 
at 4 °C at least 24 hours. Cells were then washed with 1% BSA in PBS and resuspended in 500 µL of PI-
staining solution (20 µg/mL Propidium Iodide, 10 µg/mL RNaseA, 1X PBS) at room temperature for 
30 minutes, light protected. FACS analyses were performed using the BD FACSCantoII, analyzed with 
FACSDiva software and quantified with FlowJo. A total of 104 events were acquired for each sample. 
Three independent FACS experiments were performed. 
2.6. Immunofluorescence 
For immunofluorescence analyses, cells were washed three times with PBS and fixed 10 min 
with ice-cold acetone-methanol (1:1) at room temperature. After three washes, cells were 
permeabilized with 0.25% Triton X-100 in PBS for 5 min and incubated 1 h with the primary antibody 
anti-sarcomeric MyHCs (MF20, DHSB) at room temperature. Cells were washed three times, 
permeabilized 5 min with 0.25% Triton X-100 in PBS and incubated with secondary FITC anti-mouse 
antibody (1:500, Sigma-Aldrich) plus DAPI (2 µg/mL) for 40 min at room temperature, light 
protected. The acquisition was performed by using the inverted microscope Leica DMI6000 B. Three 
independent immunofluorescence experiments were performed. 
2.7. Overexpression and RNA Interference Experiments 
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Myogenin overexpression was performed by electroporating 1 × 106 C2C12 cells with 3 µg of 
plasmid (pEMSV-Empty/pEMSV-Myog) and plating them in DM for 96 h. Cells were then collected 
and analyzed. Three independent biological replicates were performed. 
For small interfering RNA (siRNA)-mediated knockdown of NF-YB [29], 2 × 106 C2C12 cells were 
transfected by electroporation with 100 nM of NF-YB [29] or scrambled control siRNA (Qiagen, 
SI01327193) and plated into a 10 cm plate in GM condition. 72 h after transfection, cells were collected 
by scraping for total protein preparation and RNA extraction. Gene expression was analyzed 
performing real-time PCR. Two independent biological replicates of siRNA interference were 
performed. 
2.8. Chromatin Immunoprecipitation Assay (ChIP) 
ChIPs were performed as described previously [43] with the following modifications. Briefly, 2 × 
107 cells were crosslinked using 1% formaldehyde for 7 min, the reaction was quenched with 125 mM 
glycine and cells were collected by scraping. After lysis, nuclei were resuspended in Sonication buffer 
(50 mM Tris-HCl pH 8, 10 mM EDTA, 0.1% SDS, 0.5% sodium deoxycholate, protease Inhibitor cocktail) 
and sonicated (Bioruptor, Diagenode) to obtain fragments of approximately 150–300 bp, verified on 
agarose gel electrophoresis. Samples were centrifuged at 13,000 rpm for 10 min at 4 °C and supernatants 
recovered and quantified by Bradford assay. One hundred micrograms of chromatin were 
immunoprecipitated with 5 µg of anti-NF-YB (GeneSpin) and anti-FLAG (Sigma-Aldrich) antibodies. 
Protein-G beads (KPL) were used for recovery of antibody-bound proteins. Crosslinking was reversed 
by incubation at 65 °C overnight. Reactions were digested with RNase A and Proteinase K and DNA 
purified using the DNA purification kit (PCR clean Up, GeneSpin). The DNA was eluted in TE (10 mM 
Tris-HCl pH 8, 1 mM EDTA) and used in real-time PCR. Three independent biological replicates of 
ChIP experiments were performed. 
3. Results 
3.1. Ablation of NF-YA Exon 3 in C2C12 Cells by a Four Guides CRISPR/Cas9n Strategy 
Mouse C2C12 cells mostly express NF-YAl [35–38]. To study the role of this isoform in 
maintenance and differentiation of C2C12, we set out a strategy to selectively eliminate exon 3, coding 
for the 28 extra amino acids present in NF-YAl and absent in NF-YAs. We figured that the use of four 
guides flanking precisely the exon 3 regions and of the single strand-cutting Cas9-nickase (Cas9n) 
would minimize off-target effects, which potentially affect the outcome of this technology [44]. Figure 
1A shows the design of the four guide oligonucleotides, two couples targeting the 5’ and 3’ intronic 
DNA flaking exon 3, respectively. The two couples of oligos were first checked for absence of 
common genomic targets (Table S1) and cloned unpaired in the final pX330A_D10A-1x2_ad and 
pX330A_D10A-1x2_cb (Figure S1A), also expressing the Cas9n gene. The two plasmids were 
transfected in growing C2C12 cells by electroporation. Individual clones were isolated, expanded 
and analyzed by PCR, employing the amplicons shown in Figure 1B. As expected, the strategy was 
less efficient if compared to the standard use of two guides plus wt Cas9: 335 clones were individually 
screened and two were positive for correct ablation in homozygosity, as shown in Figure 1C. The 
results of PCRs of the two positive clones, #83 and #117, show the expected bands for the A, B and C 
amplicons, absent in the DNA of the parental C2C12 cells. The regions surrounding exon 3 in both 
clones were then amplified and sequenced: Figure S1B confirms the deletion of coding sequences of 
exon 3, with somewhat different ends in the two clones. In summary, we successfully ablated NF-YA 
exon 3, deriving two clones termed C2-YAl-KO. To the best of our knowledge, this is the second 
system of genome editing describing a clean deletion of an individual exon [45] and the first one 
employing the Cas9 nickase system coupled with four gRNAs. 
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Figure 1. Strategy for ablation of NF-YA exon 3 in C2C12 cells using CRISPR/Cas9n and four gRNAs. 
(A) Gene editing strategy for NF-YA exon 3 deletion using the Cas9-nickase (Cas9n) and four guide 
RNAs. The targeted sequence by each guide RNA and the deletion sites are shown. Note that Cas9n 
cuts only the DNA strand that is complementary to and recognized by the gRNA, making necessary 
the simultaneous presence of two gRNAs/Cas9n complexes to induce a double-strand break (DSB). 
(B) The three primer pairs used to check for positive C2-YAl-KO clones are shown with the specific 
amplification products highlighted by the dashed lines. (C) Example of PCR products run into a 1.2% 
agarose gel. The expected bands in control cells (ctr) are marked with arrowheads; clones #83 and 
#117 represent positive C2-YAl-KO clones. 
3.2. Characterization of C2-YAl-KO Cells 
The two C2-YAl-KO clones were characterized first for expression of NF-YA. We performed 
qRT-PCR analysis with oligos specific for the individual isoforms [46]; Figure 2A shows that the NF-
YAl mRNA is absent in the C2-YAl-KO clones. Extracts were prepared and Western blots performed: 
as expected, the parental C2C12 cells show expression of NF-YAl (Figure 2B). Instead, the clones 
express uniquely the NF-YAs isoform. We exposed the blots for long times to verify that no NF-YAl 
is visible in the two KO clones. Note that the levels of the two isoforms in parental cells—NF-YAl—
and edited clones—NF-YAs—are essentially identical, as are the levels of NF-YB and NF-YC: since 
there is an important level of autoregulation among NF-Y subunits [47], this result indicates that HFD 
subunits are available for trimer formation and DNA-binding in C2C12 and C2-YAl-KO cells. In 
summary, genetic ablation of exon 3 in C2C12 was effective, leading to generation of clones that 
express uniquely the short isoform of NF-YA at physiological levels. 
Next, we started to analyze the phenotype of the KO clones: they are stable upon repeated cycles 
of freezing and thawing and their morphology looks apparently similar to the parental C2C12 cells 
(Figure 2C). In mouse embryonic stem cells, expression of NF-YAs is associated with growth, and 
NF-YAl to differentiation [43]: in theory, NF-YAs-expressing C2C12 clones could be enhanced in 
proliferation. Cells were compared for growth under standard conditions: Figure 2D shows that 
growth curves are similar, with the two edited clones being marginally slower. In FACS analysis, we 
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did notice some differences: a higher number of S-phase and G2/M cells in the two clones (Figure S2, 
21% and 28%, with respect to 18% in C2C12). We checked the mRNA levels of PCNA, Cyclin B1/B2: 
a slight increase of Cyclin B1 and PCNA in the KO clones is observed (Figure 2E); although not 
statistically significant, this is consistent with the FACS data. The most noticeable difference, 
however, was the lower number of sub-G1 cells: 6%–7% in the two clones compared to 12% in the 
parental C2C12 cells (Figure S2): such non cycling cells are possibly undergoing cell death, suggesting 
that the switch to NF-YAs is not provoking negative effects on cellular vitality, and, if anything, the 
opposite. In summary, C2-YAl-KO clones expressing NF-YAs have an apparently normal 
morphology, grow well, but not faster, with the expected partitioning in cell cycle phases, bar slightly 
elevated G2/M and decreased sub-G1 populations. 
 
Figure 2. C2-YAl-KO clone characterization. (A) Gene expression analysis of NF-YA short and long 
levels in ctr and C2-YAl-KO clones (#83 and #117) in growth medium (GM) condition. Error bars 
represent the SD of three independent experiments. P-values were calculated using the one-sample t-
test. (B) Western blot analysis of NF-Y protein subunits (NF-YA, NF-YB, NF-YC) in ctr cells and C2-
YAl-KO clones (#83 and #117) in GM condition. For NF-YA isoforms analysis, short and long 
exposures are shown. Vinculin was used as loading control. (C) Phase contrast analysis of myoblast 
cells (ctr and C2-YAl-KO clones) morphology in GM condition. Scale bar 200 µm. (D) Proliferation 
assay performed in GM condition counting every 24 h for 3 days using the Trypan Blue dye exclusion 
test. Error bars represent the SD of three independent experiments. P-values were calculated using 
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the one-way ANOVA test. (E) Gene expression analysis of key cell-cycle regulators in ctr and C2-YAl-
KO clones (#83 and #117) in GM condition. Error bars represent the SD of three independent 
experiments. P-values were calculated using the one-sample t-test. 
3.3. C2-YAl-KO Cells Fail to Differentiate and Fuse into Myotubes 
The levels of NF-YAl drop following terminal differentiation of C2C12 cells and myotubes of 
mouse muscles show low-to-nil levels of NF-YAl [35–39]. To ascertain whether NF-YAs-expressing 
cells could form myotubes, we switched the parental C2C12 and the two C2-YAl-KO clones at 70%–
80% confluence to a differentiation medium. Before and after 72 h, we monitored cell morphology, 
performed Immunofluorescence experiments and derived whole cell extracts. Figure 3A shows that 
parental C2C12 form well organized, multinucleated myotubes, as expected (Upper Panels). The 
average number of nuclei per fiber is 15, in keeping with an efficient process (Figure 3B). On the other 
hand, the two edited clones showed a dramatic lack of myotubes formation: cells did not fuse; they 
were disorganized (Figure 3A, lower panels). We reasoned that the process could be simply slower 
in these cells and prolonged differentiation up to 5 days: this did not lead to formation of myotubes, 
nor cell fusion in the C2-YAl-KO clones (not shown). Immunofluorescence and Western blot data are 
consistent: the MyHCs marker is clearly visible in IFs (Figure 3A, right panels) and WB (Figure 3C) 
in C2C12 cells after differentiation, but not in the two edited clones. Interestingly, the levels of 
Myogenin and MyoD were substantially lower both in growing cells and at these late stages of 
differentiation in C2-YAl-KO clones. As previously reported, NF-YAl, in C2C12, and NF-YAs, in the 
edited clones, are down-regulated after 72 h of differentiation; NF-YB remained unchanged (Figure 
3C). In summary, we conclude that terminal differentiation is completely blocked in C2C12 cells 
expressing NF-YAs instead of NF-YAl. 
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Figure 3. C2-YAl-KO clones fail to differentiate into myotubes. (A) Phase contrast analysis of myoblast cells (ctr 
and C2-YAl-KO clones) before and after 72 h of differentiation (differentiation medium (DM) condition) and 
immunofluorescence analyses after 72 h of differentiation. Antibody against all sarcomeric MyHCs and DAPI 
were used. (B) Fusion index was calculated as the number of nuclei in each myotube (with three or more nuclei). 
(C) Western blot analysis of key muscle differentiation regulators (MyHCs, MyoD), NF-YA isoforms (NF-YAl, 
NF-YAs) and NF-YB proteins, before (GM) and after 72 h of differentiation (72 h DM). Vinculin was used as 
loading control. The experiment was performed three times. 
3.4. Expression of TFs in C2-YAl-KO 
We analyzed expression of MRFs and TFs with a proven role in differentiation, in the parental 
and in the C2-YAl-KO cells under growing conditions and 24 h after differentiation. Profiling 
experiments established this as an early time point to detect significant changes in gene expression 
[48]. Note that most of the TFs analyzed have CCAAT in promoters and some formally shown to be 
under NF-Y control. First, we verified expression levels of MRFs in parental C2C12 (Figure S3): 
Myogenin is robustly induced; MyoD is modestly increased; Myf5 is modestly decreased after 
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differentiation; Mef2C, but not Mef2D, is robustly increased. These changes are in agreement with 
expectations [49]. At the same time, we analyzed other TFs shown to be important for muscle 
differentiation: Six1/4/5, Snai1, Stat3 and Klf5 are all increased upon C2C12 differentiation, Id1/3 are 
modestly decreased, Pax3 is unchanged (Figure S3). These results are also in agreement with 
published data. Having established that our differentiation program runs normally in C2C12 cells, 
we monitored expression of these genes in the C2-YAl-KO clones. The results are shown in Figure 
4A for growing conditions and Figure 4B for differentiation. MRFs show the most conspicuous 
differences: Myogenin is almost undetectable in growing C2-YAl-KO clones and marginally 
increased upon differentiation. MyoD basal levels are normal, but induction is reduced upon 
differentiation, compared to parental C2C12. Myf5 expression is basally similar in the edited clones 
and higher after differentiation (Figure 4A, B). Mef2C levels are similar in growing conditions, but 
lower after differentiation: note that the levels are very low basally and differences with parental 
C2C12 cells are not statistically significant. Mef2D expression is identical in C2C12 and edited clones. 
As for the other TFs, Six1/4/5, Klf5 and Pax3 show similar expression patterns (Figure 4A,B). Minor 
changes are observed in growing conditions for Snai1, Stat3 and Id1 (one clone only) and for Id1 
(same clone) after differentiation. Finally, Id3 shows somewhat higher levels before and after 
differentiation, but again, these changes are variable in the three experiments and thus not 
statistically significant. 
To substantiate these results, protein expression of selected TFs was monitored by Western Blot 
analysis. Figure 4C shows that Myogenin levels are consistent with the mRNA data, being much 
lower in C2-YAl-KO clones than in parental cells, both in growing cells and after 24 h of 
differentiation. MyoD is substantially reduced in growing and differentiating clones, compared to 
parental C2C12. Note that protein levels were far lower than expected based on the mRNA levels, 
especially under growing conditions: this calls for post-transcriptional control in edited clones. Myf5 
protein is downregulated in C2C12 after differentiation, as expected; in edited clones, it shows lower 
levels in growing cells, but higher after induction. NF-YA and NF-YB show the expected patterns; 
Pax3 is very modestly increased in C2-YAl-KO clones and Snai1 is unchanged. In summary, C2-YAl-
KO cells have substantial differences in MRFs levels with respect to C2C12 cells, both before and after 
differentiation, whereas the other TFs showed rather minor changes. 
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Figure 4. MRFs are downregulated in C2-YAl-KO clones. (A) Gene expression analysis of key muscle 
differentiation regulators (left panel) and other TFs shown to be important for muscle differentiation 
(right panel) in GM condition. Error bars represent the SD of three independent experiments. P-values 
were calculated using the one-sample t-test. (B) Gene expression analysis of key muscle 
differentiation regulators (left panel) and other TFs shown to be important for muscle differentiation 
(right panel) 24 h after differentiation (24 h DM). Error bars represent the SD of three independent 
experiments. P-values were calculated using the one-sample t-test. (C) Western blot analysis of key 
muscle differentiation regulators (Myogenin, MyoD, Myf5), NF-YA isoforms (NF-YAl, NF-YAs) and 
NF-YB proteins and other TFs shown to be important for muscle differentiation (Pax3, Snai1), in GM 
and 24 h DM. Vinculin was used as loading control. 
3.5. Expression of Myomaker and Myomixer is activated by Myogenin and it is impaired in C2-YAl-KO 
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We were intrigued by the lack of cell fusion of the C2-YAl-KO clones after induction of 
differentiation. Myomaker—Mymk—and Myomixer—Mymx—are genes induced transcriptionally 
during muscle terminal differentiation, including in the C2C12 system [50,51]. Specifically, their 
expression is essential for the process of myocytes fusion [52]. We checked expression by qRT-PCR 
in parental C2C12 and in the two edited clones 24 h after differentiation. Figure 5A shows a strong 
induction—20-fold—of both Myomaker and Myomixer in C2C12 cells. C2-YAl-KO have much lower 
levels in growing cells (Figure 5B) and even more after differentiation (Figure 5C). 
The obvious hypothesis was that these genes are under direct NF-Y control. We surveyed their 
promoter sequences and verified that no bona fide CCAAT box is present, notably within the 
evolutionary conserved areas: given the specificity of NF-Y CCAAT recognition, we considered 
unlikely that it acts directly on their expression. Genetic experiments in zebrafish have recently 
shown that Myomaker and Myomixer are directly activated by Myogenin [53]. We analyzed 
ENCODE datasets of C2C12 cells and found that Myogenin and MyoD target both promoters. 
Myomixer has apparently one promoter, Myomaker has two promoters, some 4 kb distant from each 
other: Figure 5D shows the overlapping peaks of Myogenin and MyoD. Myogenin binds exclusively 
after 24 h of differentiation, in accordance with its induced expression. One MyoD peak is visible 
already under growing conditions on Myomaker, and two additional peaks are found at 24 h. 
Importantly, the regions bound by MyoD and Myogenin in these two promoters are conserved across 
vertebrates, as shown by PhastCons data in Figure S4A: this corroborates the functional relevance 
proven in zebrafish [53]. To verify whether Myogenin activates Myomaker and Myomixer, we 
overexpressed it in parental C2C12 and in one of the C2-YAl-KO clones (#83) and induced to 
differentiate: Western blot of Figure 5E shows the increased levels of Myogenin compared to cells 
transfected with an Empty vector control; q-RT-PCR of Figure 5F shows that Myogenin 
overexpression has negligible effects on expression of the endogenous Myomaker and Myomixer in 
parental C2C12, but it increases expression of both genes in the C2-YAl-KO cells. Finally, 
morphological observation of the edited cells shows —incomplete—improvement in differentiation 
(Figures S4B) 
In essence, we find that the marginal levels of Myogenin in C2-YAl-KO cells could result in lack 
of induction of the Myomaker and Myomixer targeted genes, entailing lack of cell fusion in NF-YAs-
expressing clones. 
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Figure 5. Myogenin directly regulates Myomaker and Myomixer expression. (A) Relative expression 
levels of Myomaker (Mymk) and Myomixer (Mymx) in C2C12 cells before and after 24 h of 
differentiation (24 h DM). Error bars represent the SD of three independent experiments. P-values 
were calculated using the one-sample t-test. (B,C) Relative expression levels of Myomaker (Mymk) 
and Myomixer (Mymx) in C2C12 cells before (B) and after 24 h of differentiation (C) in ctr and the 
two C2-YAl-KO clones. Error bars represent the SD of three independent experiments. P-values were 
calculated using the one-sample t-test. (D) ChIP-seq peaks of MyoD and Myogenin on Mymk and 
Mymx promoters in GM and after 24 h of differentiation (24 h DM) (UCSC-genome browser available 
tracks). Vertical viewing range Mymk: min 0, max 5.5. Vertical viewing range Mymx: min 0, max 8. 
(E) Western blot analysis of Myogenin protein levels in C2C12 cells transfected with a control plasmid 
(pEmpty) and the Myogenin-overexpressing plasmid (pMyog) 96 h after differentiation induction. 
Vinculin was used as loading control. (F) Relative expression levels of Mymk and Mymx in C2C12 
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Myog-overexpressing cells after 96 h of differentiation. Error bars represent the SD of three 
independent experiments. p-values were calculated using the one-sample t-test. 
3.6. Myogenin and MyoD are—Indirectly—Regulated by NF-Y 
The results shown above beg the question as to whether NF-Y directly regulates MRFs. 
Myogenin and Myf5 promoters do not contain CCAAT boxes, MyoD does [54]. To verify the NF-Y 
dependence of these genes, we transitorily inactivated NF-Y activity. In our hands, NF-YA 
inactivations by shRNA or siRNA were rather inefficient in C2C12 cells (not shown). We thus turned 
to NF-YB by treating C2C12 cells with an siRNA previously shown to be active and very specific, 
including in profiling experiments [29]. NF-YB is a necessary component of the DNA-binding trimer: 
this allows us to inhibit CCAAT-binding activity, upon siRNA treatment. Most importantly, unlike 
NF-YA, NF-YB inactivation does not trigger apoptosis [29,34], making this a suitable choice for long 
differentiation processes. Figure 6 shows the results of experiment 1, Figure S5 those of experiment 
2: in both, RT-qPCR (Figures 6A and S5A) and Western blots (Figures 6B and S5B) show far lower 
expression of NF-YB in C2C12 cells treated with NF-YB siRNA, with respect to the control siRNA. In 
mRNA analysis, Myogenin, MyoD and Mef2C, but not Myf5 nor Mef2D, are substantially 
downregulated upon NF-Y inactivation; Myomaker and Myomixer are also reduced. Six1/4/5 are 
reduced: for Six4, this in keeping with an NF-Y dependence predicted from previous data on NF-Y 
binding to a canonical promoter CCAAT [39]. As for Id1 and Id3, they are somewhat reduced, but 
the results are borderline significant: Id1 in experiment 2 and Id3 in experiment 1. We conclude that 
NF-Y removal entails a reduction of MRFs, which, in turn, could explain the observed drop of 
Myomaker and Myomixer. We also show that members of the Six family are NF-Y targets. Analysis 
of proteins levels in extracts of siRNA-inactivated cells by Western blots confirmed these results: the 
levels of NF-YB were lower (although not to the extent of the mRNA) and paralleled by somewhat 
lower levels of NF-YA. Myogenin is substantially decreased and MyoD is also affected, to a lesser 
extent (Figures 6B and S5B). We conclude that NF-Y regulates the expression of MyoD and Myogenin 
in C2C12 cells. 
The Myogenin promoter is CCAAT-less and was not bound by NF-Y in C2C12 cells [39] and, 
despite the presence of a canonical CCAAT, the MyoD promoter was also not bound [39]. To 
understand whether the positive effect of NF-Y on MyoD is direct, we checked the parental C2C12 
cells for the presence of NF-Y in ChIP experiments. Three independent experiments are shown in 
Figures 6C and S5C. The absence of enrichment of NF-Y on MyoD is indeed confirmed, whereas the 
Stard4 positive control promoter is clearly bound. Equally positive was the promoter of Id1, but not 
that of Id3. Note that there is variability in the fold-enrichments in the three experiments: as this is 
high (from 60 to 800-folds), we consider quantitative changes difficult to interpret, especially when 
compared to completely negative promoters such as MyoD and Id3. Therefore, we conclude that NF-
Y does not regulate MyoD directly—and despite promoter binding—NF-Y has modest effects on Id1 
transcription in C2C12 cells. 
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Figure 6. Analysis of NF-Y involvement in muscle specific genes expression. (A) Gene expression 
analysis of NF-YB and key muscle differentiation regulators in C2C12 cells 72 h after NF-YB silencing 
(siNF-YB) and scrambled siRNA control. Error bars represent the SD of two different RT-qPCR 
replicates. P-values were calculated using the one-sample t-test. (B) Western blot analysis of NF-YB, 
NF-YA and key muscle differentiation regulators (Myogenin, MyoD) protein levels 72 h after NF-YB 
silencing (siNF-YB) and the scrambled siRNA control. Vinculin was used as loading control. (C) ChIP 
experiment performed on C2C12 ctr cells in GM condition using NF-YB and negative control (nc) 
antibodies. The unrelated region (ur) and Stard4 were used as negative and positive control, 
respectively. Results are represented as the input percentage of each sample normalized to the input 
percentage of the nc antibody. 
4. Discussion 
By genome editing, we derived clones of C2C12 cells that express NF-YAs instead of NF-YAl. 
We verified that NF-YAs—and companion HFDs—are expressed at comparable levels and that it 
decreases after differentiation. The edited C2C12 clones are stable, grow normally, yet they are 
completely deficient in differentiation. We report defects of basal and induced expression of 
Myomaker and Myomixer, early response-genes likely responsible for lack of cell fusion. Their 
promoters are targeted by MyoD and Myogenin. In turn, we find low—basal and induced—levels of 
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MyoD and Myogenin in the NF-YAs-expressing clones. Finally, expression of both MRFs are 
indirectly controlled by NF-Y. 
4.1. Role of NF-YA Alternative Splicing in Muscle Cells 
Specific isoforms of TFs have long been known to impact heavily on transcriptional regulation. 
Paradigmatic examples are the members of the p53/p63/p73 families, whose isoforms, produced by 
multiple promoters and alternative splicing, have different targets and often opposing transcriptional 
effects [55]. The muscle system is no exception [56,57]. Mef2C and Mef2D undergo alternative splicing 
during muscle differentiation [57,58]: a muscle-specific isoform of Mef2D contains exon α2 rather 
than α1, both expressed in muscle cells. Growing and early differentiating cells harbors MEF2Dα1; 
the switch to MEF2Dα2 occurs in terminal stages of C2C12 differentiation, leading to activation of 
late genes. MEF2Dα1 is phosphorylated at two serines by PKA [59], which mediate association with 
HDACs, resulting in repression. MEF2Dα2 lacks these residues, functioning as a transcriptional 
activator. Parallel molecular mechanisms appear to be operating for the related MEF2Cα1/α2 
alternative splicing isoforms [58]. The key issue in Mef2 splicing regulation is involvement in late 
stages of differentiation. Alternative splicing was reported for the master TFs of muscle commitment 
PAX3 and PAX7, but the functional roles of the single isoforms are less well characterized [60–64]. 
We show here that a switch from NF-YAl to NF-YAs causes a major difference in the 
differentiation properties of C2C12 cells. The major NF-YA isoforms, originally reported decades ago 
[32], are only recently attracting the attention they deserve. In part, this was due to the elusive logic 
of their expression patterns: in some systems, cells have NF-YAs before—and NF-YAl after—
differentiation; in others, such as in muscle cells, NF-YAl is mostly found. In part, it was because of 
the rather unimpressive nature of the exon 3 amino acids incorporated into NF-YAl: a short stretch 
rich in glutamines and hydrophobic residues amid the larger transactivation domain. Overexpression 
experiments suggested differences in gene activation [39,65], but these experiments are to be taken 
with a grain of salt, because of the large amount of proteins produced, targeting the large number of 
potential NF-Y sites in the genome. NF-YA AS is likely more complex than what is shown here. First, 
NF-YAx is another alternatively spliced isoform, recently reported in glioblastomas, devoid of exons 
3 and 5: this greatly reduces the activation domain, with important functional consequences [66]. 
Expression of NF-YAx will have to be monitored in normal cells, to verify whether it is specific for 
glioblastomas. Second, there are micro differences—6 amino acids—produced in many cell types 
within the acceptor site of exon 5. Third, some cells show the inclusion of an additional Gln residue 
at the acceptor splicing site of exon 3, producing a 29 amino acids insertion [32]. Note that a similar 
situation was reported for PAX3, in which an extra Gln causes differences in DNA-binding affinity 
[59]. Precise editing techniques, as we have started to use here in C2C12 cells, could sort out the 
functionality of the various isoforms. 
4.2. NF-Y Does Not Target Directly Genes Involved in C2C12 Differentiation 
Sequence-specific TFs target specific genomic sites, driven by the discriminatory power of their 
DNA-binding Domains. However, they are also known to be binding indirectly, being tethered by 
other TFs or complexes: analysis of genomic locations by ENCODE has shown that this latter 
mechanism is far from marginal [67]. In addition to ENCODE, several independent ChIP-seq of TFs—
and cofactors—identified binding to CCAAT locations [68]. One such example regards the orphan 
receptor Rev-Erb, important for muscle regeneration, targeting NF-Y sites in C2C12 cells [69]. The 
reverse, namely NF-Y being tethered to CCAAT-less locations by other TFs, has yet to be described. 
The issue could theoretically be relevant, since the genes down-regulated after NF-Y removal, or by 
switching from NF-YAl to NF-YAs, have generally no CCCAT in promoters. The effects appear to be 
largely indirect, but we do not favor the promoter tethering hypothesis. Rather, we report binding of 
Myogenin and MyoD to the promoters of Myomaker and Myomixer and show that Myogenin 
overexpression leads to recovery of their expression in C2-YAl-KO cells. This extends to mouse cells 
genetic experiments made in zebrafish [53]. It also indicates that NF-Y does not regulate other TFs 
essential for expression of these two genes. In summary, NF-Y/CCAAT interactions in promoters, 
Cells 2020, 9, 789 16 of 21 
 
which are structurally identical for NF-YAl and NF-YAs, are likely not crucial for genes induced 
during myotubes formation: rather, the focus is shifted to the control of MRFs, or other TFs. 
We have analyzed expression of TFs involved in myoblast/C2C12 differentiation. The majority 
are not dramatically altered in edited clones. Mef2C induction is impaired, but previous studies 
indicated that NF-Y is bound to the Mef2D, not to Mef2C promoter [39]. We find that Mef2C, not 
Mef2D, is regulated by NF-YB RNAi interference. Note that these TFs are also targeted by MyoD and 
Myogenin, as they play a role in the final stages of differentiation [7,59]. This suggests indirect 
regulation by NF-Y via MRFs. Id1/Id3 do have bona fide functional CCAAT in promoters [70], bound 
in cancer cells as per ENCODE data (M. Ronzio, A.B., D.D., R.M., in preparation) and in NTera2 cells 
[71]: Id1, but not Id3, is bound in vivo by NF-Y in C2C12, parental cells and edited clones. The levels 
are decreased in C2-YAl-KO upon differentiation, but NF-Y-inactivation brings very marginal 
decrease in Id1 expression. PAX3, which acts upstream of MyoD, shows variable, somewhat 
increased mRNA levels in the edited clones, but this is not supported by analysis of protein levels. In 
summary, there is no clear CCAAT-driven TF that could explain the phenotype: instead, we propose 
that the decrease of Myogenin and MyoD expression entails a cascade of transcriptional events 
leading to failure of differentiation (Figure 7). 
 
Figure 7. NF-YA isoforms involvement in regulation of expression of muscle genes. Model for NF-
YA isoforms mediated regulation of expression of muscle genes in growth condition (left panel) and 
differentiation condition (right panel). 
4.3. NF-Y Regulates MRFs Expression Indirectly 
Switching from NF-YAl to NF-YAs—and NF-YB inactivation—negatively affects MRFs 
expression. Myf5 is moderately down in growing cells, remaining somewhat higher after 
differentiation. NF-Y-inactivation leads to a severe drop in Myogenin expression and a decrease of 
MyoD, which indicates an impact of NF-Y on their expression. The regulation appears to be 
transcriptional for Myogenin, not for MyoD, whose mRNA levels are variable, but overall similar. 
The Myogenin promoter is CCAAT-less and an indirect effect of NF-Y must be invoked. As for MyoD, 
the promoter harbors a high affinity NF-Y site, extremely conserved in evolution [54] and at the 
expected position (at -70 from TSS). Yet, NF-Y is not bound in vivo (Figure 6C). This is the only such 
example in nearly 200 promoters for which genetic analysis was reported [72]. The combination of 
an evolutionarily conserved, canonical CCAAT in a standard promoter position might function 
through NF-Y somewhen during the physiological activation of MyoD in development, while it has 
become expendable in the C2C12 system. Thus, down-regulation of MyoD in NF-YAs-expressing 
cells is also an indirect effect. It was proposed that MyoD serves as “pioneer” TF predisposing 
chromatin configurations for Myogenin to act as powerful activator of terminal differentiation genes 
and repressor of cell-cycle genes [73]. The latter function might be robustly counteracted by NF-YAs, 
but we have no evidence of that (Figure 2). It is now clear that the focus is set on transcriptional 
regulation of the MyoD and Myogenin units and on which activator TF(s)—or cofactor(s)—is under 
NF-YAl—but not NF-YAs—direct control. For the time being, the “candidate” TFs approach used 
here failed to offer a plausible explanation on how NF-YAl regulates MRFs expression, thereby 
muscle differentiation. We must resolve to more systematic analysis, such as RNA-seq, to identify 
potential NF-Y-mediated regulators in C2C12. In light of the low intrinsic levels of muscle-
commitment by MRFs in C2-YAl-KO clones, such analysis could also shed light on the actual identity 
of these cells. 
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Supplementary Materials: The following are available online at www.mdpi.com/2073-4409/9/3/789/s1, Figure 
S1: CRISPR/Cas9n system and ablation of NF-YA exon 3 in C2C12 cells. (A) Schematic representation of plasmids 
construction, following the Multiplex CRISPR/Cas9n Assembly System Kit protocol (Yamamoto lab) [40]. (B) 
Sequencing of the two C2-YAl-KO clones (#83, #117) compared to the control (ctr). Deleted sequence, targeted 
sequence and exon 3 sequence are highlighted. Figure S2: Cell-cycle analysis of C2-YAl-KO clones. Flow 
cytometry analysis of ctr C2C12 cells and the two C2-YAl-KO clones in GM condition. The analysis of three 
independent experiments and the average of percentage of cells in each cell-cycle phase are shown. Figure S3: 
Gene expression analysis of TFs in growing and differentiated C2C12 cells. Gene expression analysis by RT-
qPCR of key muscle differentiation regulators (left panel) and other TFs shown to be important for muscle 
differentiation (right panel) in GM condition and 24 h after differentiation in C2C12 ctr cells. Error bars represent 
the SD of three different experiments. P-values were calculated using the one-sample t-test. Figure S4: Myomaker 
and Myomixer expression are regulated by MyoD and Myogenin. (A) UCSC view of Mymk and Mymk loci 
showing alignment of ChIP-Seq data and DNA regulatory motifs conserved across Vertebrates by PhastCons. 
(B) Phase-contrast analysis of C2C12 cells (ctr and #83) morphology transfected with pEmpty or pMyog, 96 h 
after differentiation. Figure S5: Analysis of NF-Y involvement in muscle specific genes expression. (A) Gene 
expression analysis by RT-qPCR of NF-YB and key muscle differentiation regulators in C2C12 cells 72 h after 
NF-YB silencing (siNF-YB) and the scrambled siRNA control (II° experiment). Error bars represent the SD of two 
different q-PCR replicates. p-values were calculated using the one-sample t-test. (B) Western blot analysis of NF-
YB, NF-YA and key muscle differentiation regulators (Myogenin, MyoD) protein levels 72 h after NF-YB 
silencing (siNF-YB) and the scrambled control. Vinculin was used as loading control. (C) Analysis of II° and III° 
ChIP experiments performed on C2C12 ctr cells in GM condition using NF-YB antibody and the negative control 
(nc). The unrelated region (ur) and Stard4 were used as negative and positive control, respectively. Results are 
represented as the input percentage of sample normalized to the nc. Table S1: Off-targets analysis. Analysis of 
possible off-target sites of each gRNA using the online tool https://crispr.cos.uni-heidelberg.de. For each gRNA 
the off-target gene name, gene id, position (intronic, intergenic, exonic), mismatches (MM) and the PAM 
sequence are reported. Table S2: Primers used. The specific sequence of each primer (forward and reverse) used 
for RT-qPCR and ChIP analysis are reported. 
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